Leo Wealth LLC Sells 376 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Leo Wealth LLC trimmed its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 37.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 635 shares of the biopharmaceutical company’s stock after selling 376 shares during the period. Leo Wealth LLC’s holdings in Regeneron Pharmaceuticals were worth $452,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Financial Advocates Investment Management bought a new stake in Regeneron Pharmaceuticals in the 4th quarter valued at $474,000. Private Wealth Management Group LLC lifted its position in shares of Regeneron Pharmaceuticals by 260.0% during the 4th quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company’s stock valued at $38,000 after acquiring an additional 39 shares during the period. Tectonic Advisors LLC grew its stake in Regeneron Pharmaceuticals by 16.6% during the fourth quarter. Tectonic Advisors LLC now owns 830 shares of the biopharmaceutical company’s stock worth $591,000 after buying an additional 118 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in Regeneron Pharmaceuticals by 21.6% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 55,426 shares of the biopharmaceutical company’s stock valued at $38,305,000 after purchasing an additional 9,845 shares in the last quarter. Finally, Paragon Capital Management Inc. acquired a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at about $1,257,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Shares of Regeneron Pharmaceuticals stock opened at $710.00 on Friday. Regeneron Pharmaceuticals, Inc. has a 12 month low of $642.00 and a 12 month high of $1,211.20. The firm has a market capitalization of $78.02 billion, a P/E ratio of 17.57, a P/E/G ratio of 1.60 and a beta of 0.08. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. The business has a fifty day simple moving average of $716.62 and a two-hundred day simple moving average of $913.59.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $11.21 by $0.86. The company had revenue of $3.79 billion during the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 33.61% and a return on equity of 16.88%. Regeneron Pharmaceuticals’s revenue was up 10.3% on a year-over-year basis. During the same period last year, the company posted $11.86 EPS. On average, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.75 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be given a $0.88 dividend. The ex-dividend date is Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.50%.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on REGN shares. Bank of America reaffirmed an “underperform” rating and issued a $565.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 10th. Sanford C. Bernstein reduced their price target on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating for the company in a report on Tuesday, January 7th. Royal Bank of Canada decreased their price target on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating for the company in a research note on Friday, November 1st. Canaccord Genuity Group assumed coverage on Regeneron Pharmaceuticals in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price objective for the company. Finally, Robert W. Baird dropped their price target on shares of Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating on the stock in a research report on Wednesday. One analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $973.13.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.